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Summary
Aims. Bisphosphonates (BPs) are important therapeutic drugs
in multiple myeloma and cancers with bone metastases. Bis-
phosphonate-Related Osteonecrosis of the Jaw (BRONJ) has
been described as a potential side effect of the last generation
BPs. The Authors evaluated clinical features, preventing mea-
sures and treatment strategies.
Patients and methods. The Authors retrospectively analyzed
19 patients affected by malignant cancer in endovenous treat-
ment with BPs. Fourteen patients were treated with zole-
dronate, 1 with pamidronate and 4 with both drugs for breast
cancer (9 patients), multiple myeloma (6 patients), prostatic
cancer (3 patients) and colon cancer (1 patient).
Results. The lenght of therapy was 5-36 months before os-
teonecrosis was observed; in 15 patients BRONJ involved the
mandible, in 2 the maxilla and in 2 both jaws. The trigger fac-
tors were tooth extractions, inadequate removable total den-
ture, basic and advanced surgery, root canal treatment. Ten
patients received non-surgical treatment, 7 patients minor sur-
gical procedures and 2 patients a partial maxillectomy. Heal-
ing was achieved in all maxillary localization, and in one
mandibular localization with partial maxillectomy.
Conclusions. Prevention is the best important phase in the
management of this pathology. Risk factors are the type of
bisphosphonate and the length of exposure, while dental sur-
gical procedures are trigger factors. Conservative treatment
seems to be the best way to control BRONJ, but bone resec-
tion and soft tissue closure have to be performed when the le-
sion is refractory to conservative approach.
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Introduction
Bisphosphonates stand as an important group of drugs for the
treatment of metabolic and oncologic pathologies involving the
skeletal system.
Bisphophonates act by inhibiting osteoclastic bone resorp-
tion. The most common drugs utilized in the prevention and
therapy of osteoporosis are: alendronate, risendronate, iban-
dronate. 
Pamidronate and zolendronate are utilized in the prophylaxis of
bone complications and in the hypercalcemia associated to
multiple myeloma and to metastatic bone disease due to breast
and prostatic cancer (1-3). 
All these chemical substances are characterized by a high
power and selectivity. Nowadays, literature is demonstrating
the correlation between chronic bisphosphonate assumption
and jaw’s osteonecrosis onset (4-19). 
Aims
The purposes of this report are: to describe Bisphosphonate-
Related Osteonecrosis of the Jaw (BRONJ) clinical aspects
and to describe possible preventing measures and treatment
strategies of BRONJ.
Background
First reports on BRONJ were published in 2003 (4). Since then,
a study with 63 cases published by Ruggiero (6), one with 119
cases by Marx (20), one with 10 cases by Bagan (21) along
with some case reports and case series provide more informa-
tion on BRONJ features (22-26). 
In the literature BRONJ’s incidence ranges from 0.01% with
oral administration to 0.8-12% with intravenous injection (12).
One of the main BRONJ risk factors is the bisphosphonate
therapy length with a high risk of complications in patients
treated for more than 12 months (10, 27).
From 1998 to 2004 Research on Adverse Drugs Events and
Reports identified 561 cases of ONJ in patients with cancer
treated with zolendronate (28). In the position paper of the
American Academy of Oral and Maxillofacial Pathology 368
cases were published from 2004 to 2006 (11). 
Nowadays every year 300.000 oncologic patients are treated
with zoledronic acid in Italy and from 2003 to 2005 zoledronic
acid prescriptions have been increased by 18% (29). These
epidemiologic data show the importance in evaluating bisphos-
phonate associated morbidity. 
In accordance with the American Association of Oral and Max-
illofacial Surgery (12) and with the majority of the Authors (11,
13) the main risk factors for BRONJ development are:
– drugs related (administration way and length of therapy);
– local risk factors (basic or advanced oral surgery with bone
injury; oral hygiene; smoke; alcohol; local anatomy; inade-
quate removable total denture; oral pathologies; infection
and/or ischemic susceptible factors such as diabetes; high
dose steroid treatment; radiant therapy; anemia; blood clot
disease; etc.);
– demographic and systemic factors (age; race; neoplastic
pathology; associated therapies).
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Patients and methods
From February 2004 to September 2006 19 patients with bis-
phosphonate endovenous treatment and with BRONJ came to
the Oral Surgery Department of the Florence University Hospi-
tal (18, 19). The mean age was 66.4 ± 11.7 years.
In 14 patients the used bisphosphonate was zolendronate, in 1
patient pamidronate and in 4 patients both drug were adminis-
trated. The mean interval administration was 12 months (mini-
mum 5 months, maximum 36).
In 9 patients (47,4%) the oncologic disease was breast cancer;
in 6 patients (31,5%) it was myeloma; in 3 (15,8%) it was pro-
static cancer; and in 1 (5%) patient it was colon cancer. All the
patients were chosen following strict diagnostic criteria. The
most frequent symptoms in the early stage were: spontaneous
pain, swelling, odontogenic abscesses, oral fistula, bone expo-
sure due to mucous ulcer, post-extraction alveolitis, and local
lymphadenopathy.
The trigger factors were considered to be tooth extractions, local
concussion (inadequate removable total denture, edentulous
ridges), root canal treatment, basic and advanced surgery. In
some cases it was not possible to identificate a trigger factor.
Pre-existing inflammatory lesions and other pharmacological
treatments appeared to worsen the development of the disease.
The treatment of this lesion is extremely difficult and prolonged.
There are no data to support any therapeutic choice: surgery
often worsens the pathology.
Surgical curettage to achieve mechanical debridement is indi-
cated in patients with no complications. Chemical debridement
is carried out with antiseptic irrigations and with iodine gouze.
Re-infection prevention is improved by local ointment use and
0.12% chlorexidine daily rinses. 
Surgical procedures to achieve a mechanical debridement of
necrotic tissue, broad spectrum antibiotic treatment for a long
period, and local antibiotic use are useful before clinical lesion
changes with bone exposure and small bone sequestra.
More invasive surgical treatments (such as deeper curettage,
sequestrectomies, large resections and vascularized bone
grafts) are indicated after clinical changes characterized by clini-
cal symptoms (pain, fever), oral or extra oral fistula, necrotic tis-
sue, pathologic fractures and ineffective antibiotic treatment.
The necrotic tissue curettage, sequestrectomy, sliding flap pro-
cedure (in two cases with oro-antral communication), and pe-
duncle vascularized bone graft (in case with fracture) (Fig. 1)
were the surgical treatments used in order to stop osteonecrot-
ic lesion progress.
Metastatic foci were not shown by histological examination
both in the lesion core and in the neighbouring bone tissue.
Macroscopic healthy bone samples showed cortical necrosis
with well preserved lamellar bone. Furthermore, empty osteo-
cytic lacunae were detected and midullary bone tissue ap-
peared necrotic.
Results
In most of the cases complete healing was not observed, al-
though therapeutic protocol was strictly applied (18, 19). All
cases of maxillary location reached complete healing. 
On the contrary we observed only symptoms of improvement
when the location was mandibular, probably for the reduced re-
generative capacity at this site (Table I). 
Following American Association of Oral and Maxillofacial Surgery
(12) staging and treatment criteria, two different clinical cours-
es have been identified:
1) early clinical course, where small bone sequestrum can be
assessed (Fig. 2);
2) late clinical course, where large necrotic areas worsened by
suppurative phlogosis can be detected (Fig. 3).
Clinical Cases in Mineral and Bone Metabolism 2007; 4(1): 48-52 49
Bisphosphonate-related osteonecrosis of the jaw: the Florence experience
Table I - Results of the study.
Outcome Localization n° Treatment Prognosis
Healing Upper jaw 2 Minor surgery Follow up 1 year
Lower jaw 1 Bone resection and vascularized bone graft Follow up 6 months
Prolonged controlled phase Lower jaw 9 Mouth rinse, strict clinical follw up, 
no surgery/minor surgery ?
Large necrosis phase Lower jaw 5 Bad clinical condition,  inauspicious
and complications not recommended surgery
Death Lower jaw 1 Bone resection and vascularized bone graft
Upper and lower jaw 1 Mouth rinse, strict clinical follw up, 
no surgery/minor surgery
Figure 1 - CT scan: bone necrosis with pathologic fracture.
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Discussion
Up to 2002 BRONJ incidence was lower than 1 out of 10.000
treated patients (4, 5). The use of the last generation bisphos-
phonates (i.e. zoledronate) increased the incidence of BRONJ
up to an endemic behavior (6-9). All patients observed had bis-
phosphonate endovenous treatment with administration inter-
vals of 30 days. Our data, in agreement with what published,
showed a higher incidence in patients treated with zoledronate
(Zometa) and pamidronate (Aredia). On the other hand these
kind of lesions were seldom detected in patients treated with
aledronate (Fosamax) and risedronate (Actonel). Clinical pic-
tures varied from the more frequent limited osteonecrosis ar-
eas with or without suppurative phlogosis to the larger os-
teonecrotic areas with suppurative phlogosis, jaw fractures and
extra-oral fistulae (Fig. 4).
The role of bisphosphonates in the onset of the lesion is con-
firmed by the time elapsed between drug assumption and le-
sion development, that seems to be around 18 months for zole-
dronate and 6 year for pamidronate (10), even thought the le-
sion can onset even after 5 months of treatment (9-14, 30).
All the patients of our study underwent a drug treatment longer
than 6 months. For many Authors long periods of drug treat-
ment is a risk factor (as chemotherapeutic treatment, myeloma,
renal failure, hypoproteinemia, steroid therapy, anemia, blood
clot disease, infections, etc.) (8, 11-14, 31-34).
Patients under chemotherapeutic and corticosteroid treatment
and patients who underwent radiant therapy presented larger
tissue necrosis and refractoriness to our therapeutic protocol.
In our study osteonecrotic lesions preferential location was in
the lower jaw. This location seems to be explained by anatomic
local factors such as terminal vascularization and by a lower
quantity of trabecular bone in the mandible than in the upper
jaw (35).
Actually even spontaneous lesions (incidence 22-30%) (14, 36)
are due to microinjures; these lesions are more frequent in the
lingual posterior areas of the lower jaw. Indeed in this region
mucosa is very thin and there are higher trauma due to remov-
able denture and higher masticatory forces (4, 20, 31).
In the majority of cases the clinical picture evolved in two phas-
es: in the first phase small multiple bone sequestra are domi-
nant with a good therapeutic response; the following phase is
characterized by a large suppurative necrotic area in which far-
macologic treatment becomes inefficient.
We have seen a clinical change after which the conservative
treatment led to poor results and in these cases a more inva-
sive treatment should be indicated (Fig. 5).
Hellstein et al. (7) suggest the surgical treatment only when in-
fection cannot be controlled but large bone resections should
always be avoided (4, 9, 11, 37).
According to Ruggiero et al. (38-40) the clinician should adopt
different treatment protocols on the basis of patient’s character-
istic lesions.
In order to trace guidelines American Association of Oral and
Maxillofacial Surgery (12) suggested four staging categories
(risk category and stage 1, 2, 3) for the patient who underwent
endovenous or oral bisphosphonate treatments (38).
The interruption of bisphosphonate assumption is one of the
most difficult decision and should be taken in agreement with
the oncologist. According to Migliorati et al. (9) the discontinua-
tion of bisphosphonate treatment is mandatory, even though
there is no immediate clinical improvement.
Figure 2 - Panoramic radiograph demonstrating a bone sequestrum
area.
Figure 3 - Large neocrotic areas with suppurative phlogosis.
Figure 4 - Submental region: extra-oral fistula. Figure 5 - Emimandibulectomy.
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Robinson (31) contraindicates any surgical treatment when the
patient is taking bisphosphonates, as the implant treatment is
doomed to failure in patient with bisphosphonate treatment. In
an experimental study Narai (41) assessed a dangerous torque
during implant placement.
In a patient treated with zoledronate reaching our observation
for an exposed bone in the implant area with a wide bone
necrotic area developed after implant surgery. This patient was
treated with broad spectrum antibiotics for a long period of time
(Fig. 6).
One should not generalize on bisphosphonate morbidity, as
there are some molecules as clodronate, that can improve im-
plant stability and osteointegration (42).
Hyperbaric treatment is considered by many Authors with no
effect (9, 43). In our experience patients treated with antibiotic
and hyperbaric chamber showed a good soft tissue regenera-
tion (18), making possible to conclude that hyperbaric treat-
ment represents a good aid in soft tissue management (44,
45).
Conclusions
After numerous reports published in the last four years about
the adverse effects of biphosphonates on bone health, many
Organizations [Novartis (14), American Academy of Oral Medi-
cine (13), American Academy of Oral and Maxillofacial Pathol-
ogy (11), and American Association of Oral and Maxillofacial
Surgeons (12)] elaborated the precautionary measure guide-
lines on diagnosis and treatment of BRONJ in oncologic pa-
tients treated with endovenous bisphosphonates (46).
We added more information about prevention and treatment
strategies. Prevention is of primary importance in patients who
need bisphosphonate treatment (11-14, 47-50). It is, therefore,
necessary:
a) close dialogue between dentist, oral pathologyst, oncologist
and physician;
b) patients must be informed of these complications in order to
do not underestimate some early symptoms;
c) general detailed anamnesis;
d) specific oral anamnesis (facial pain, swelling and chewing im-
pairment, oral mucosa status and progressive oral surgery
treatment);
e) evaluation of all systemic and local risk factors;
f) informed consensus;
g) strumental evaluation: panoramic X-ray and TC. Patients
should take a panoramic X-ray for compromised tooth ex-
tractions. A TC-99mT can help in detecting possible lesions
and “increased uptake areas” or “cold spots”. Cold spots
could stand for cavitary necrosis;
h) all dental procedures should be completed (48);
i) do not wear inadequate total removable denture;
j) strict hygiene control.
Treatment strategies are based on BRONJ staging. The treat-
ment objectives for patients with BRONJ are to eliminate pain,
control infections of the soft and hard tissues and minimize the
progression or occurrence of bone necrosis (12).
According to our clinical experience, there is not a clear corre-
lation between tooth extraction and BRONJ onset. A clinical
picture showing dental suffering represent a suspected os-
teonecrotic area. Leaving these lesions untreated means to
promote a quicker and heavier osteonecrotic lesion expansion
(swelling, abscesses, mucous/cutaneous fistulae).
In these patients therapeutic choices must be guided by the le-
sion clinical features, applying a conservative protocols in the
early stage and resective surgery in the late stage of the
pathology.
Bisphosphonate drugs should be administered only to the most
severe oncologic cases: patients with normal calcemic pictures
or with stable bone metastatic disease have not be treated.
However, bisphosphonates represent a therapeutic possibility
irreplaceable for many patients affected by neoplastic patholo-
gies. Bisphosphonate morbidity appears in a limited group of
patients. It becomes therefore essential to genetically identify a
subclass of patients at risk of osteonecrosis.
Our group is researching a possible genetic profile implicated
in the development of BRONJ also searching for genetic mark-
ers, useful to detect pharmacogenetic differences before the
start of treatment.
Clinical research about this pathology requires a multicentric
study. A common data base collecting all epidemiologic and
clinical data is essential to reach a deeper knowledge on the
management of BRONJ patient.
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